The submission of a supplemental application to the FDA for expanded use of CARVYKTI indicates that Legend Biotech is seeking to broaden the market for its cancer treatment drug. If the FDA approves the application, it could lead to increased sales and revenue for the company, which would likely have a positive impact on its stock price.